Human tissue kallikrein induces hypotension in transgenic mice

Hypertension

Volumn 23, Issue 2, 1994, Pages 236-243

  Wang, Jing ^a   Xiong, William ^a   Yang, Zhirong ^a   Davis, Tia ^b   Dewey, Michael J ^b   Chao, Julie ^a   Chao, Lee ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

aprotinin; gene expression; hypotension; kallikrein; mice, transgenic

Indexed keywords

KALLIKREIN;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TRANSGENIC MOUSE;

EID: 0027976094     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.23.2.236     Document Type: Article

References (28)

1. Bhoola DK, Figueroa CD, Worthy K. Bioregulation of kinins: kininogens and kininases. Pharmacol Rev. 1992;44:1-80.
2. Elliot R, Nuzum FR. Urinary excretion of a depressor substance (kallikrein of Frey and Kraut) in arterial hypertension. Endocrinology. 1934;18:462-474.
3. Margolius HS, Geller RG, Pisano JJ, Sjoerdsma A. Altered urinary kallikrein excretion in human hypertension. Lancet. 1971;2: 1063-1065.
4. Carretero OA, Scicli AG. The renal kallikrein-kinin system in human and experimental essential hypertension. Clin Wochenschr. 1971;56(suppl 1):113-125.
5. Margolius HS, Horwitz D, Pisano JJ, Keiser HR. Urinary kallikrein in hypertension: relationship to sodium intake and sodium-retaining steroid. Circ Res. 1974;35:820-825.
6. Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash O, Kuida H, Williams RR. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension. 1989;13:3-8.
7. Overlack A, Stumpe KO, Kolloch R, Ressel C, Krueck F. Antihy-pertensive effect of orally administered glandular kallikrein in essential hypertension: results of a double blind study. Hypertension. 1981;3:118-121.
8. Ogawa K, Ito T, Ban M, Mochizuki M, Satake T. Effects of orally administered glandular kallikrein on urinary kallikrein and prostaglandin excretion, plasma immunoreactive prostanoids and platelet aggregation in essential hypertension. Klin Wochenschr. 1985;63:332-336.
9. Woodley-Miller CM, Chao J, Chao L. Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. J Hypertens. 1989;7:865-871.
10. Pravenec M, Ken V, Kunes J, Scicli G, Carretero OA, Simonet L, Kurtz TW. Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension. 1991;17:242-246.
11. Carretero OA, Polomski C, Hampton A, Scicli AG. Urinary kallikrein, plasma renin and aldosterone in New Zealand genetically hypertensive (GH) rats. Clin Exp Pharmacol Physiol. 1976;3:55-59.
12. Carretero OA, Amin VM, Ocholik T, Scicli AG, Koch J. Urinary kallikrein in rats bred for their susceptibility and resistance to the hypertensive effect of salt. Circ Res. 1978;42:727-731.
13. Ader JL, Tran-Van T, Praddaude F. Low urinary excretion of active and total kallikrein in young spontaneously hypertensive rats and effect of long-term angiotensin converting enzyme inhibition. J Hypertens. 1986;4(suppl 5):151-153.
14. Ader JL, Tran-Van T, Praddaude F. Renal tissue kallikrein in newborn and young SHR. Am J Hypertens. 1987;1(suppl):53S-55S.
15. Durnam DM, Palmiter RD. Transcriptional regulation of the mouse metallothionein-1 gene by heavy metals. J Biol Chem. 1981; 256:5712-5716.
16. Evans BA, Yun ZX, Close JA, Tregear GW, Kitamura N, Nakanishi S, Callen DF, Baker E, Hyland VJ, Sutherland GR, Richards RI. Structure and chromosomal localization of the human renal kallikrein gene. Biochemistry. 1988;27:3124-3129.
17. Chirgwin JA, Przbyla A, McDonald R, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979;18:5294-5299.
18. Shimamoto K, Chao J, Margolius HS. The radioimmunoassay of human urinary kallikrein and comparisons with kallikrein activity measurements. J Clin Endocrinol Metab. 1980;51:840-848.
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193: 265-275.
20. Jaffa AA, Harvey JN, Sutherland SE, Margolius HS, Mayfield RK. Renal kallikrein responses to dietary protein: a possible mediator of hyperfiltration. Kidney Int. 1989;36:1003-1010.
21. Dyer KR, Messing A. Metal-inducible pathology in the liver, pancreas, and kidney of transgenic mice expressing SV40 early region genes. Am J Pathol. 1989;135:401-410.
22. Shimamoto K, Mayfield RK, Margolius HS, Chao J, Stroud W, Kaplan AP. Immunoreactive tissue kallikrein in human serum. J Lab Clin Med. 1984;103:731-738.
23. Chen Z, Bode W. Refined 2.5 Å x-ray crystal structure of the complex formed by porcine kallikrein A and the bovine pancreatic trypsin inhibitor: crystallization, Patterson search, structure deter-mination, refinement, structure and comparison with its components and with the bovine trypsin-pancreatic trypsin inhibitor complex. J Mol Biol. 1983;164:283-311.
24. Geiger R, Fink E, Lottspeich F, Henschen A, Fritz H. Human urinary kallikrein-biochemistry and physiological studies. Fresenius Z Anal Chem. 1980;301:172-173.
25. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic mice harboring the mouse ren-2 gene. Nature. 1990;344: 541-544.
26. Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension. 1990;16:301-307.
27. Chagas JR, Hirata IY, Juliano MA, Xiong W, Wang C, Chao J, Juliano L, Prado ES. Substrate specificities of tissue kallikrein and T-kininogenase: their possible role in kininogen processing. Biochemistry. 1992;31:4969-4974.
28. Shimamoto K, Ando T, Nakao T, Tanaka S, Sakuma M, Miyahara M. A sensitive radioimmunoassay method for urinary kinin in man. J Lab Clin Med. 1978;91:721-728.